Academic medical centre Hospital for Special Surgery (HSS) stated on Tuesday that the approved immunosuppressive drug anakinra used to treat rheumatoid arthritis and neonatal-onset multisystem inflammatory disease may allow certain people with COVID-19 to avoid mechanical ventilation.
Based on a case study from investigators at HSS, anakinra appears to reduce the effects of systemic inflammation in people with COVID-19 who are in severe respiratory distress. The study, published online-first in Arthritis & Rheumatology, was led by Iris Navarro-Millán, MD, MSPH. Dr Navarro-Millán is now developing a controlled study of anakinra in patients with COVID-19 who fit into the criteria.
The patients with acute hypoxic respiratory failure (AHRF) and cytokine storm syndrome (CSS) are the two criteria identified as signals that a patient would soon require mechanical ventilation. CSS is the most dangerous consequence leading to fatality in people with COVID-19. AHRF is defined as an increased need for supplemental oxygen. Since the COVID-19 pandemic began, a number of immunosuppressive drugs have been evaluated in patients experiencing CSS. Some of these drugs, including anakinra, inhibit a protein called interleukin-1.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial